GOVX

GeoVax Labs Inc

Add to Watchlist

Advanced Chart

0.677

-0.002(-0.295%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.6805

Open

0.6799

VWAP

0.67

Vol

154.78K

Mkt Cap

17.22M

Low

0.6703

Amount

104.10K

EV/EBITDA(TTM)

Total Shares

2.53M

14.13M

EV/OCF(TTM)

P/S(TTM)

1.20

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

0.00

-100%

0.00

-100%

0.00

-100%

Estimates Revision

The market is revising Upward the revenue expectations for GeoVax Labs, Inc. (GOVX) for FY2025, with the revenue forecasts being adjusted by 2.63% over the past three months. During the same period, the stock price has changed by -26.76%.

Revenue Estimates for FY2025

Revise Upward

+2.63%

In Past 3 Month

Stock Price

Go Down

-26.76%

In Past 3 Month

3 Analyst Rating

1498.52% Upside

Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 10.83 USD with a low forecast of 8.50 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

1498.52% Upside

Current: 0.677

Low

8.50

Averages

10.83

High

14.00

1498.52% Upside

Current: 0.677

Low

8.50

Averages

10.83

High

14.00

Alliance Global Partners

Buy

maintain

$8.50

2025-06-18

Reason

Alliance Global Partners

Price Target

$8.50

2025-06-18

maintain

Buy

Reason

Alliance Global Partners reiterates a Buy rating and $8.50 price target on shares of GeoVax Labs, telling investors in a research note that the positive Scientific Advice from the European Medicines Agency regarding their GEO-MVA candidate vaccine for the prevention of Mpox and smallpox provides a clear regulatory pathway ahead, and if successful, could lead to a potential accelerated regulatory approval timeline. This feedback also comes as the World Health Organization issued its fourth declaration of Mpox as a Public Health Emergency of International Concern, further reiterating the need to create preventative measures for Mpox, the firm says.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$18 → $14

2025-04-15

Reason

D. Boral Capital

Jason Kolbert

Price Target

$18 → $14

2025-04-15

Maintains

Strong Buy

Reason

D. Boral Capital lowered the firm's price target on GeoVax Labs to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government's convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abrupt termination raises concerns about the future trajectory of GeoVax's vaccine development efforts and its financial implications, says D. Boral Capital. The firm has removed all BARDA revenues and stockpile awards that were in its model.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$18

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$18

2025-04-10

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$18

2025-03-28

Reason

D. Boral Capital

Jason Kolbert

Price Target

$18

2025-03-28

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$18

2025-02-27

Reason

D. Boral Capital

Jason Kolbert

Price Target

$18

2025-02-27

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for GeoVax Labs Inc (GOVX.O) is -0.41, compared to its 5-year average forward P/E of -2.53. For a more detailed relative valuation and DCF analysis to assess GeoVax Labs Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.53

Current PE

-0.41

Overvalued PE

2.47

Undervalued PE

-7.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.41

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.47

Undervalued EV/EBITDA

-3.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

58.40

Current PS

22.69

Overvalued PS

175.81

Undervalued PS

-59.00

Financials

Annual

Quarterly

FY2025Q2

YoY :

+183.45%

852.28K

Total Revenue

FY2025Q2

YoY :

+7.05%

-5.42M

Operating Profit

FY2025Q2

YoY :

+6.04%

-5.37M

Net Income after Tax

FY2025Q2

YoY :

-82.41%

-0.35

EPS - Diluted

FY2025Q2

YoY :

+123.85%

-4.35M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

-94.18%

-446.02

FCF Margin - %

FY2025Q2

YoY :

-62.59%

-630.05

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

742.0

USD

Months

3-6

33.9K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

742.0

USD

Months

3-6

33.9K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

GOVX News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

14:40:07

HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital

2025-06-16 (ET)

2025-06-16

16:41:20

GeoVax Labs files to sell 6.15M common units

2025-06-16

10:59:06

GeoVax Labs receives favorable European regulatory guidance supporting GEO-MVA

News

4.0

08-07Benzinga

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $9 Price Target

9.0

07-16PRnewswire

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

1.0

07-14Globenewswire

Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream

People Also Watch

JVA

Coffee Holding Co Inc

Aprea Therapeutics Inc

Millennium Group International Holdings Ltd

Odyssey Marine Exploration Inc

American Shared Hospital Services

Brand House Collective Inc

FAQ

What is GeoVax Labs Inc (GOVX) stock price today?

The current price of GOVX is 0.6775 USD — it has decreased -0.29 % in the last trading day.

GOVX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

GOVX News & Events

Events Timeline

News

People Also Watch

FAQ

What is GeoVax Labs Inc (GOVX) stock price today?

What is GeoVax Labs Inc (GOVX)'s business?

What is the price predicton of GOVX Stock?

What is GeoVax Labs Inc (GOVX)'s revenue for the last quarter?

What is GeoVax Labs Inc (GOVX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for GeoVax Labs Inc (GOVX)'s fundamentals?

How many employees does GeoVax Labs Inc (GOVX). have?

What is GeoVax Labs Inc (GOVX) market cap?